Clinical Trial: Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)

U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07706530) titled 'Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)' on July 10.

Brief Summary: Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheumatologic Score (ACR) and key secondary outcomes are the change on ACR20% at week 16 and ACR50/70% at week 24. Eligible patients will be randomly assigned (1:1:1) to receive oral CBP-0276 200mg QD, 800mg QD or placebo for CBP-0276 for 24 weeks

Study Start Dat...